top of page
news and events
Five Abstracts Accepted at ESMO, SITC, and CICON 2025
Accession Therapeutics is pleased to announce that five abstracts showcasing the company’s TROCEPT cancer immunotherapy platform have been accepted for presentation at three leading international oncology conferences in 2025.
Sep 9
Accession Therapeutics obtains approval for first TROCEPT cancer clinical trial in UK
Accession Therapeutics obtains approval for first TROCEPT cancer clinical trial in UK
Jan 30
Accession Therapeutics submits CTA to the UK MHRA to start Phase 1 first-in-human clinical trial with lead TROCEPT anti-cancer immunotherapy
Milestone reached in under three years from company inception
Sep 4, 2024
Accession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidate
Accession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidate
Apr 25, 2024
Chief Business Officer appointed at Accession Therapeutics as company prepares for clinical trials
Chief Business Officer appointed at Accession Therapeutics as immune-oncology company prepares for clinical trials in 2024
Jul 19, 2023
Accession Therapeutics presented some of the exciting preclinical data for our lead programme
Accession Therapeutics presented some of the exciting preclinical data for our lead programme #TROCEPT-01 at the recent 37th Annual...
Jan 4, 2023
bottom of page